Skip to main content
Premium Trial:

Request an Annual Quote

MeMed COVID-19 Prognostic Test Receives CE Mark

NEW YORK – Infectious disease diagnostics firm MeMed said on Tuesday that it has received the CE mark for its COVID-19 management tool MeMed COVID-19 Severity.

The test measures multiple host-response proteins in serum to determine whether a COVID-19 patient is likely to experience severe outcomes, allowing doctors to distinguish between patients who may need higher levels of care and those who can safely self-isolate at home.

The test runs on Haifa, Israel-based MeMed's point-of-need platform, the MeMed Key, and returns results in 15 minutes.

“Highly sensitive and accurate diagnostic and prognostic tests are key tools for clinicians," Sergey Motov, professor of emergency medicine, Maimonides Medical Center, said in a statement. "Tools like MeMed COVID-19 Severity are a win-win solution: Doctors can assess the likelihood of patients suffering from severe complications, enabling tailored treatments or discharge if the risk of deteriorating is low."

"I’m excited to begin deploying a pioneering solution to help identify COVID-19 patients at risk of severe outcomes, empowering physicians to manage what is increasingly likely to become an endemic situation," said Eran Eden, MeMed's cofounder and CEO. "MeMed COVID-19 Severity is also relevant for authorities contemplating preparedness for future pandemics."

The company said it plans to offer the test in Europe both directly and through commercial partners.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.